For Inflectra® (infliximab) Prescribing Information for Great Britain click here.
Adverse event reporting information can be found at the bottom of the page.
Rheumatoid Arthritis Selected Important Safety Information
The Inflectra Summary of Product Characteristics (SmPC) should be read and understood in full before prescribing this medicine.1
Inflectra MUST NOT be given in:
- Cases of tuberculosis, or other severe infections such as sepsis, abscesses and opportunistic infections
- Patients with a history of hypersensitivity to infliximab (or any of its excipients) or other murine proteins
- Patients with moderate or severe heart failure (NYHA class III/IV)
Also consider the safety and screening recommendations below for any patient diagnosed with Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and severe plaque psoriasis for whom you are considering initiating Inflectra:1
Actively screen and monitor patients for infections
Screenings for latent/active tuberculosis and hepatitis B (before, during and for six month after completion of treatment)
Vaccinate
If possible, it is recommended that patients be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Inflectra therapy. Patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6 of the SmPC).
Monitor
The general condition of patients (particularly symptoms of bacterial, invasive viral infections, fever, ulcers, or purulent discharge from fistulas). Infliximab should not be initiated in patients with Crohn's and acute suppurative fistulas until the source of the infection is fully diagnosed.
Be aware that TNF alpha suppression may mask symptoms of infection such as fever.
Discontinue infliximab if patient develops a new serious infection or sepsis.
Discuss with patients and follow up on these potential health issues
- Heart problems
- Lymphoma or other cancer
- Lung disease or heavy smoking
- Conditions that affect the nervous system, such as multiple sclerosis, Guillain-Barre syndrome, and optic neuritis
- Abnormal skin openings
- Imminent operations
- Dental issues, including planned operations or procedures
- Haematologic abnormalities (e.g. persistent fever, bruising, etc)
- Symptoms and signs of liver dysfunction
Consider the long half-life of infliximab when planning certain vaccinations or surgical procedures
Closely monitor patients who require surgery for infections
Avoid concurrent administration of Inflectra with live vaccines or therapeutic infectious agents such as live attenuated bacteria
Also avoid administration of live vaccines in infants ‚≤6 months of age who have been exposed to infliximab in utero
The administration of live vaccines to a breastfed infant when the mother is receiving infliximab is not recommended unless infant infliximab serum levels are undetectable.
Summary of the safety profile
Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in clinical trials, occurring in 25.3% of infliximab-treated patients compared with 16.5% of control patients. The most serious ADRs associated with the use of TNF blockers that have been reported for infliximab include HBV reactivation, CHF (congestive heart failure), serious infections (including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn's disease), and serious infusion reactions (see section 4.4 in SmPC). Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last dose of treatment.
Description of selected adverse drug reactions
Infusion-related reactions
An infusion-related reaction was defined in clinical studies as any adverse event occurring during an infusion or within 1 hour after an infusion. In Phase III clinical studies, 18% of infliximab-treated patients compared with 5% of placebo-treated patients experienced an infusion-related reaction. Overall, a higher proportion of patients receiving infliximab monotherapy experienced an infusion-related reaction compared to patients receiving infliximab with concomitant immunomodulators.
Immunogenicity
Patients who developed antibodies to infliximab were more likely (approximately 2-3 fold) to develop infusion-related reactions. Use of concomitant immunosuppressant agents appeared to reduce the frequency of infusion-related reactions.
Infections
Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients receiving infliximab. Some of these infections have been fatal; the most frequently reported opportunistic infections with a mortality rate of >5% include pneumocystosis, candidiasis, listeriosis and aspergillosis (see section 4.4 of the SmPC).
Juvenile rheumatoid arthritis patients
Infliximab was studied in a clinical study in 120 patients (age range: 4-17 years old) with active juvenile rheumatoid arthritis despite methotrexate. Patients received 3 or 6 mg/kg infliximab as a 3-dose induction regimen (weeks 0, 2, 6 or weeks 14, 16, 20, respectively) followed by maintenance therapy every 8 weeks, in combination with methotrexate.
Infusion reactions
Infusion reactions occurred in 35% of patients with juvenile rheumatoid arthritis receiving 3 mg/kg compared with 17.5% of patients receiving 6 mg/kg. In the 3 mg/kg infliximab group, 4 out of 60 patients had a serious infusion reaction and 3 patients reported a possible anaphylactic reaction (2 of which were among the serious infusion reactions). In the 6 mg/kg group, 2 out of 57 patients had a serious infusion reaction, one of whom had a possible anaphylactic reaction (see section 4.4 of the SmPC).
Immunogenicity
Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of patients receiving 6 mg/kg. The antibody titres were notably higher for the 3 mg/kg compared to the 6 mg/kg group.
Infections
Infections occurred in 68% (41/60) of children receiving 3 mg/kg over 52 weeks, 65% (37/57) of children receiving infliximab 6 mg/kg over 38 weeks and 47% (28/60) of children receiving placebo over 14 weeks (see section 4.4 of the SmPC).
Explore more
Evidence – Rheumatoid arthritis
Learn about the clinical evidence supporting the use of Inflectra in patients with rheumatoid arthritis
Rheumatoid arthritis dosing
Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis
Find out more
- Inflectra Summary of Product Characteristics.
Quick Links
Read about the safety profile and contraindications with Inflectra in patients with Crohn's disease.
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?